KOLON TISSUEGENE COMPLETES PATIENT DOSING IN TWO PIVOTAL US PHASE III CLINICAL TRIALS FOR TG-C ...Middle East

Completed patient dosing in US Phase 3 clinical trials. There will be a two-year follow-up period, followed by submission of the Biologics License Application (BLA) to permit marketing of TG-C once approved. ROCKVILLE, Md., July 11, 2024 /PRNewswire/ -- Kolon TissueGene, Inc. ('the...

Hence then, the article about kolon tissuegene completes patient dosing in two pivotal us phase iii clinical trials for tg c was published today ( Thursday 11/07/2024 - 07:20 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( KOLON TISSUEGENE COMPLETES PATIENT DOSING IN TWO PIVOTAL US PHASE III CLINICAL TRIALS FOR TG-C )

Also on site :

• Hyland and AWS Bring the Content‑Powered Agentic Enterprise to Asia‑Pacific, Meeting Customers Where Their Data Lives
• Carnival Data Incident - Exposes Nearly 6 Million Travelers' Private Data - Poynter Law Group Investigates
• Bambu Lab lanza A2L: Espacio creativo. Extra grande